Drug Trial Radar · NCT00004288
Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis
Last checked: Nov 20, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4
Actual
Start
May 1996
Primary completion
Not stated
Study completion Dec 1999
Sponsor
- Lead sponsor
- National Center for Research Resources (NCRR)NIH
- Sponsor type
- NIH
- Collaborators
- University of Rochester
- First posted
- Oct 19, 1999
Design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OBJECTIVES: I. Assess the safety and efficacy of olsalazine, a dimer of 5-aminosalicylic acid, in men with ankylosing spondylitis unresponsive to nonsteroidal anti-inflammatory drugs and physiotherapy.
Conditions
- Ankylosing Spondylitis
Interventions
olsalazineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.